6 O
ADVERSE O
REACTIONS O
EXCERPT O
: O
The O
most O
common O
adverse O
reactions O
in O
patients O
with O
advanced O
renal O
cell O
carcinoma O
( O
> O
=20 O
% O
) O
are O
diarrhea O
, O
hypertension O
, O
hair O
color O
changes O
( O
depigmentation O
) O
, O
nausea O
, O
anorexia O
, O
and O
vomiting O
. O

( O
6.1 O
) O
The O
most O
common O
adverse O
reactions O
in O
patients O
with O
advanced O
soft O
tissue O
sarcoma O
( O
> O
=20 O
% O
) O
are O
fatigue O
, O
diarrhea O
, O
nausea O
, O
decreased O
weight O
, O
hypertension O
, O
decreased O
appetite O
, O
hair O
color O
changes O
, O
vomiting O
, O
tumor O
pain O
, O
dysgeusia O
, O
headache O
, O
musculoskeletal O
pain O
, O
myalgia O
, O
gastrointestinal O
pain O
, O
and O
dyspnea O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
GlaxoSmithKline O
at O
1-888-825-5249 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
with O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

Potentially O
serious O
adverse O
reactions O
with O
VOTRIENT O
included O
: O
* O
Hepatotoxicity B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
QT B-OSE_Labeled_AE
prolongation I-OSE_Labeled_AE
and O
torsades B-OSE_Labeled_AE
de I-OSE_Labeled_AE
pointes I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Cardiac B-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Hemorrhagic B-OSE_Labeled_AE
events I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Arterial B-OSE_Labeled_AE
and O
venous O
thromboembolic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
and O
5.6 O
) O
] O
* O
Thrombotic B-OSE_Labeled_AE
microangiopathy I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
* O
Gastrointestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
and O
fistula O
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
* O
Interstitial B-OSE_Labeled_AE
Lung I-OSE_Labeled_AE
Disease I-OSE_Labeled_AE
( O
ILD O
) O
/ O
Pneumonitis B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
* O
Reversible B-OSE_Labeled_AE
Posterior I-OSE_Labeled_AE
Leukoencephalopathy I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
( O
RPLS O
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.10 O
) O
] O
* O
Hypertension B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.11 O
) O
] O
* O
Infection B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.15 O
) O
] O
* O
Increased B-NonOSE_AE
toxicity I-NonOSE_AE
with O
other O
cancer O
therapies O
[ O
see O
Warnings O
and O
Precautions O
( O
5.16 O
) O
] O
Renal B-Not_AE_Candidate
Cell I-Not_AE_Candidate
Carcinoma I-Not_AE_Candidate
: O
The O
safety O
of O
VOTRIENT O
has O
been O
evaluated O
in O
977 O
patients O
in O
the O
monotherapy O
trials O
which O
included O
586 O
patients O
with O
RCC B-Not_AE_Candidate
at O
the O
time O
of O
NDA O
submission O
. O

With O
a O
median O
duration O
of O
treatment O
of O
7.4 O
months O
( O
range O
: O
0.1 O
to O
27.6 O
) O
, O
the O
most O
commonly O
observed O
adverse O
reactions O
( O
> O
=20 O
% O
) O
in O
the O
586 O
patients O
were O
diarrhea B-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE
, O
hair B-OSE_Labeled_AE
color I-OSE_Labeled_AE
change I-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
anorexia B-OSE_Labeled_AE
, O
and O
vomiting B-OSE_Labeled_AE
. O

The O
data O
described O
below O
reflect O
the O
safety O
profile O
of O
VOTRIENT O
in O
290 O
RCC B-Not_AE_Candidate
patients O
who O
participated O
in O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
[ O
see O
Clinical O
Studies O
( O
14.1 O
) O
] O
. O

The O
median O
duration O
of O
treatment O
was O
7.4 O
months O
( O
range O
: O
0 O
to O
23 O
) O
for O
patients O
who O
received O
VOTRIENT O
and O
3.8 O
months O
( O
range O
: O
0 O
to O
22 O
) O
for O
the O
placebo O
arm O
. O

Forty-two O
percent O
of O
patients O
on O
VOTRIENT O
required O
a O
dose O
interruption O
. O

Thirty-six O
percent O
of O
patients O
on O
VOTRIENT O
were O
dose O
reduced O
. O

Table O
1 O
presents O
the O
most O
common O
adverse O
reactions O
occurring O
in O
> O
=10 O
% O
of O
patients O
who O
received O
VOTRIENT O
. O

Table O
1 O
. O

Adverse O
Reactions O
Occurring O
in O
> O
=10 O
% O
of O
Patients O
with O
RCC O
Who O
Received O
VOTRIENT O
VOTRIENT O
Placebo O
( O
N O
= O
290 O
) O
( O
N O
= O
145 O
) O
All O
Gradesa O
Grade O
3 O
Grade O
4 O
All O
Gradesa O
Grade O
3 O
Grade O
4 O
Adverse O
Reactions O
% O
% O
% O
% O
% O
% O
Diarrhea B-OSE_Labeled_AE
52 O
3 O
< O
1 O
9 O
< O
1 O
0 O
Hypertension B-OSE_Labeled_AE
40 O
4 O
0 O
10 O
< O
1 O
0 O
Hair B-OSE_Labeled_AE
color I-OSE_Labeled_AE
changes I-OSE_Labeled_AE
38 O
< O
1 O
0 O
3 O
0 O
0 O
Nausea B-OSE_Labeled_AE
26 O
< O
1 O
0 O
9 O
0 O
0 O
Anorexia B-OSE_Labeled_AE
22 O
2 O
0 O
10 O
< O
1 O
0 O
Vomiting B-OSE_Labeled_AE
21 O
2 O
< O
1 O
8 O
2 O
0 O
Fatigue B-OSE_Labeled_AE
19 O
2 O
0 O
8 O
1 O
1 O
Asthenia B-OSE_Labeled_AE
14 O
3 O
0 O
8 O
0 O
0 O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
11 O
2 O
0 O
1 O
0 O
0 O
Headache B-OSE_Labeled_AE
10 O
0 O
0 O
5 O
0 O
0 O
a O
National O
Cancer O
Institute O
Common O
Terminology O
Criteria O
for O
Adverse O
Events O
, O
version O
3 O
. O

Other O
adverse O
reactions O
observed O
more O
commonly O
in O
patients O
treated O
with O
VOTRIENT O
than O
placebo O
and O
that O
occurred O
in O
< O
10 O
% O
( O
any O
grade O
) O
were O
alopecia B-OSE_Labeled_AE
( O
8 O
% O
versus O
< O
1 O
% O
) O
, O
chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
5 O
% O
versus O
1 O
% O
) O
, O
dysgeusia B-OSE_Labeled_AE
( O
altered B-OSE_Labeled_AE
taste I-OSE_Labeled_AE
) O
( O
8 O
% O
versus O
< O
1 O
% O
) O
, O
dyspepsia B-OSE_Labeled_AE
( O
5 O
% O
versus O
< O
1 O
% O
) O
, O
dysphonia B-OSE_Labeled_AE
( O
4 O
% O
versus O
< O
1 O
% O
) O
, O
facial B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
( O
1 O
% O
versus O
0 O
% O
) O
, O
palmar B-OSE_Labeled_AE
- I-OSE_Labeled_AE
plantar I-OSE_Labeled_AE
erythrodysesthesia I-OSE_Labeled_AE
( O
hand B-OSE_Labeled_AE
- I-OSE_Labeled_AE
foot I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
) O
( O
6 O
% O
versus O
< O
1 O
% O
) O
, O
proteinuria B-OSE_Labeled_AE
( O
9 O
% O
versus O
0 O
% O
) O
, O
rash B-OSE_Labeled_AE
( O
8 O
% O
versus O
3 O
% O
) O
, O
skin B-OSE_Labeled_AE
depigmentation I-OSE_Labeled_AE
( O
3 O
% O
versus O
0 O
% O
) O
, O
and O
weight B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
( O
9 O
% O
versus O
3 O
% O
) O
. O

Additional O
adverse O
reactions O
from O
other O
clinical O
trials O
in O
RCC B-Not_AE_Candidate
patients O
treated O
with O
VOTRIENT O
are O
listed O
below O
: O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
Connective I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
: O
Arthralgia B-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
spasms I-OSE_Labeled_AE
. O

Table O
2 O
presents O
the O
most O
common O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
occurring O
in O
> O
10 O
% O
of O
patients O
who O
received O
VOTRIENT O
and O
more O
commonly O
( O
> O
=5 O
% O
) O
in O
patients O
who O
received O
VOTRIENT O
versus O
placebo O
. O

Table O
2 O
. O

Selected O
Laboratory O
Abnormalities O
Occurring O
in O
> O
10 O
% O
of O
Patients O
with O
RCC O
Who O
Received O
VOTRIENT O
and O
More O
Commonly O
( O
> O
=5 O
% O
) O
in O
Patients O
Who O
Received O
VOTRIENT O
versus O
Placebo O
VOTRIENT O
Placebo O
( O
N O
= O
290 O
) O
( O
N O
= O
145 O
) O
All O
Gradesa O
Grade O
3 O
Grade O
4 O
All O
Gradesa O
Grade O
3 O
Grade O
4 O
Parameters O
% O
% O
% O
% O
% O
% O
Hematologic B-NonOSE_AE
Leukopenia B-OSE_Labeled_AE
37 O
0 O
0 O
6 O
0 O
0 O
Neutropenia B-OSE_Labeled_AE
34 O
1 O
< O
1 O
6 O
0 O
0 O
Thrombocytopenia B-OSE_Labeled_AE
32 O
< O
1 O
< O
1 O
5 O
0 O
< O
1 O
Lymphocytopenia B-OSE_Labeled_AE
31 O
4 O
< O
1 O
24 O
1 O
0 O
Chemistry B-NonOSE_AE
ALT B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
53 O
10 O
2 O
22 O
1 O
0 O
AST B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
53 O
7 O
< O
1 O
19 O
< O
1 O
0 O
Glucose B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
41 O
< O
1 O
0 O
33 O
1 O
0 O
Total B-OSE_Labeled_AE
bilirubin I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
36 O
3 O
< O
1 O
10 O
1 O
< O
1 O
Phosphorus B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
34 O
4 O
0 O
11 O
0 O
0 O
Sodium B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
31 O
4 O
1 O
24 O
4 O
0 O
Magnesium B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
26 O
< O
1 O
1 O
14 O
0 O
0 O
Glucose B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
17 O
0 O
< O
1 O
3 O
0 O
0 O
a O
National O
Cancer O
Institute O
Common O
Terminology O
Criteria O
for O
Adverse O
Events O
, O
version O
3 O
. O

Soft B-Not_AE_Candidate
Tissue I-Not_AE_Candidate
Sarcoma I-Not_AE_Candidate
: O
The O
safety O
of O
VOTRIENT O
has O
been O
evaluated O
in O
382 O
patients O
with O
advanced O
soft B-Not_AE_Candidate
tissue I-Not_AE_Candidate
sarcoma I-Not_AE_Candidate
, O
with O
a O
median O
duration O
of O
treatment O
of O
3.6 O
months O
( O
range O
: O
0 O
to O
53 O
) O
. O

The O
most O
commonly O
observed O
adverse O
reactions O
( O
> O
=20 O
% O
) O
in O
the O
382 O
patients O
were O
fatigue B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
weight I-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
, O
tumor B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
hair B-OSE_Labeled_AE
color I-OSE_Labeled_AE
changes I-OSE_Labeled_AE
, O
musculoskeletal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
dysgeusia B-OSE_Labeled_AE
, O
dyspnea B-OSE_Labeled_AE
, O
and O
skin B-OSE_Labeled_AE
hypopigmentation I-OSE_Labeled_AE
. O

The O
data O
described O
below O
reflect O
the O
safety O
profile O
of O
VOTRIENT O
in O
240 O
patients O
who O
participated O
in O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
[ O
see O
Clinical O
Studies O
( O
14.2 O
) O
] O
. O

The O
median O
duration O
of O
treatment O
was O
4.5 O
months O
( O
range O
: O
0 O
to O
24 O
) O
for O
patients O
who O
received O
VOTRIENT O
and O
1.9 O
months O
( O
range O
: O
0 O
to O
24 O
) O
for O
the O
placebo O
arm O
. O

Fifty-eight O
percent O
of O
patients O
on O
VOTRIENT O
required O
a O
dose O
interruption O
. O

Thirty-eight O
percent O
of O
patients O
on O
VOTRIENT O
had O
their O
dose O
reduced O
. O

Seventeen O
percent O
of O
patients O
who O
received O
VOTRIENT O
discontinued O
therapy O
due O
to O
adverse O
reactions O
. O

Table O
3 O
presents O
the O
most O
common O
adverse O
reactions O
occurring O
in O
> O
=10 O
% O
of O
patients O
who O
received O
VOTRIENT O
. O

Table O
3 O
. O

Adverse O
Reactions O
Occurring O
in O
> O
=10 O
% O
of O
Patients O
with O
STS O
Who O
Received O
VOTRIENT O
VOTRIENT O
Placebo O
( O
N O
= O
240 O
) O
( O
N O
= O
123 O
) O
All O
Gradesa O
Grade O
3 O
Grade O
4 O
All O
Gradesa O
Grade O
3 O
Grade O
4 O
Adverse O
Reactions O
% O
% O
% O
% O
% O
% O
Fatigue B-OSE_Labeled_AE
65 O
13 O
1 O
48 O
4 O
1 O
Diarrhea B-OSE_Labeled_AE
59 O
5 O
0 O
15 O
1 O
0 O
Nausea B-OSE_Labeled_AE
56 O
3 O
0 O
22 O
2 O
0 O
Weight B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
48 O
4 O
0 O
15 O
0 O
0 O
Hypertension B-OSE_Labeled_AE
42 O
7 O
0 O
6 O
0 O
0 O
Appetite B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
40 O
6 O
0 O
19 O
0 O
0 O
Hair B-OSE_Labeled_AE
color I-OSE_Labeled_AE
changes I-OSE_Labeled_AE
39 O
0 O
0 O
2 O
0 O
0 O
Vomiting B-OSE_Labeled_AE
33 O
3 O
0 O
11 O
1 O
0 O
Tumor B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
29 O
8 O
0 O
21 O
7 O
2 O
Dysgeusia B-OSE_Labeled_AE
28 O
0 O
0 O
3 O
0 O
0 O
Headache B-OSE_Labeled_AE
23 O
1 O
0 O
8 O
0 O
0 O
Musculoskeletal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
23 O
2 O
0 O
20 O
2 O
0 O
Myalgia B-OSE_Labeled_AE
23 O
2 O
0 O
9 O
0 O
0 O
Gastrointestinal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
23 O
3 O
0 O
9 O
4 O
0 O
Dyspnea B-OSE_Labeled_AE
20 O
5 O
< O
1 O
17 O
5 O
1 O
Exfoliative B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
18 O
< O
1 O
0 O
9 O
0 O
0 O
Cough B-OSE_Labeled_AE
17 O
< O
1 O
0 O
12 O
< O
1 O
0 O
Peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
14 O
2 O
0 O
9 O
2 O
0 O
Mucositis B-OSE_Labeled_AE
12 O
2 O
0 O
2 O
0 O
0 O
Alopecia B-OSE_Labeled_AE
12 O
0 O
0 O
1 O
0 O
0 O
Dizziness B-OSE_Labeled_AE
11 O
1 O
0 O
4 O
0 O
0 O
Skin B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
b O
11 O
2 O
0 O
1 O
0 O
0 O
Skin B-OSE_Labeled_AE
hypopigmentation I-OSE_Labeled_AE
11 O
0 O
0 O
0 O
0 O
0 O
Stomatitis B-OSE_Labeled_AE
11 O
< O
1 O
0 O
3 O
0 O
0 O
Chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
10 O
2 O
0 O
6 O
0 O
0 O
a O
National O
Cancer O
Institute O
Common O
Terminology O
Criteria O
for O
Adverse O
Events O
, O
version O
3 O
. O
b O
27 O
of O
the O
28 O
cases O
of O
skin B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
were O
palmar B-OSE_Labeled_AE
- I-OSE_Labeled_AE
plantar I-OSE_Labeled_AE
erythrodysesthesia I-OSE_Labeled_AE
. O

Other O
adverse O
reactions O
observed O
more O
commonly O
in O
patients O
treated O
with O
VOTRIENT O
that O
occurred O
in O
> O
=5 O
% O
of O
patients O
and O
at O
an O
incidence O
of O
more O
than O
2 O
% O
difference O
from O
placebo O
included O
insomnia B-OSE_Labeled_AE
( O
9 O
% O
versus O
6 O
% O
) O
, O
hypothyroidism B-OSE_Labeled_AE
( O
8 O
% O
versus O
0 O
% O
) O
, O
dysphonia B-OSE_Labeled_AE
( O
8 O
% O
versus O
2 O
% O
) O
, O
epistaxis B-OSE_Labeled_AE
( O
8 O
% O
versus O
2 O
% O
) O
, O
left B-OSE_Labeled_AE
ventricular I-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
( O
8 O
% O
versus O
4 O
% O
) O
, O
dyspepsia B-OSE_Labeled_AE
( O
7 O
% O
versus O
2 O
% O
) O
, O
dry B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
( O
6 O
% O
versus O
< O
1 O
% O
) O
, O
chills B-OSE_Labeled_AE
( O
5 O
% O
versus O
1 O
% O
) O
, O
vision B-OSE_Labeled_AE
blurred I-OSE_Labeled_AE
( O
5 O
% O
versus O
2 O
% O
) O
, O
and O
nail B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
( O
5 O
% O
versus O
0 O
% O
) O
. O

Table O
4 O
presents O
the O
most O
common O
laboratory B-NonOSE_AE
abnormalities I-NonOSE_AE
occurring O
in O
> O
10 O
% O
of O
patients O
who O
received O
VOTRIENT O
and O
more O
commonly O
( O
> O
=5 O
% O
) O
in O
patients O
who O
received O
VOTRIENT O
versus O
placebo O
. O

Table O
4 O
. O

Selected O
Laboratory O
Abnormalities O
Occurring O
in O
> O
10 O
% O
of O
Patients O
with O
STS O
Who O
Received O
VOTRIENT O
and O
More O
Commonly O
( O
> O
=5 O
% O
) O
in O
Patients O
Who O
Received O
VOTRIENT O
versus O
Placebo O
VOTRIENT O
Placebo O
( O
N O
= O
240 O
) O
( O
N O
= O
123 O
) O
All O
Gradesa O
Grade O
3 O
Grade O
4 O
All O
Gradesa O
Grade O
3 O
Grade O
4 O
Parameters O
% O
% O
% O
% O
% O
% O
Hematologic B-NonOSE_AE
Leukopenia B-OSE_Labeled_AE
44 O
1 O
0 O
15 O
0 O
0 O
Lymphocytopenia B-OSE_Labeled_AE
43 O
10 O
0 O
36 O
9 O
2 O
Thrombocytopenia B-OSE_Labeled_AE
36 O
3 O
1 O
6 O
0 O
0 O
Neutropenia B-OSE_Labeled_AE
33 O
4 O
0 O
7 O
0 O
0 O
Chemistry B-NonOSE_AE
AST B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
51 O
5 O
3 O
22 O
2 O
0 O
ALT B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
46 O
8 O
2 O
18 O
2 O
1 O
Glucose B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
45 O
< O
1 O
0 O
35 O
2 O
0 O
Albumin B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
34 O
1 O
0 O
21 O
0 O
0 O
Alkaline B-OSE_Labeled_AE
phosphatase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
32 O
3 O
0 O
23 O
1 O
0 O
Sodium B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
31 O
4 O
0 O
20 O
3 O
0 O
Total B-OSE_Labeled_AE
bilirubin I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
29 O
1 O
0 O
7 O
2 O
0 O
Potassium B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
16 O
1 O
0 O
11 O
0 O
0 O
a O
National O
Cancer O
Institute O
Common O
Terminology O
Criteria O
for O
Adverse O
Events O
, O
version O
3 O
. O

Diarrhea B-NonOSE_AE
: O
Diarrhea B-OSE_Labeled_AE
occurred O
frequently O
and O
was O
predominantly O
mild O
to O
moderate O
in O
severity O
in O
both O
the O
RCC B-Not_AE_Candidate
and O
STS B-Not_AE_Candidate
clinical O
trials O
. O

Patients O
should O
be O
advised O
how O
to O
manage O
mild O
diarrhea B-NonOSE_AE
and O
to O
notify O
their O
healthcare O
provider O
if O
moderate O
to O
severe O
diarrhea B-NonOSE_AE
occurs O
so O
appropriate O
management O
can O
be O
implemented O
to O
minimize O
its O
impact O
. O

Lipase B-NonOSE_AE
Elevations I-NonOSE_AE
: O
In O
a O
single-arm O
RCC B-Not_AE_Candidate
trial O
, O
increases B-OSE_Labeled_AE
in O
lipase I-OSE_Labeled_AE
values O
were O
observed O
for O
27 O
% O
( O
48/181 O
) O
of O
patients O
. O

Elevations B-OSE_Labeled_AE
in O
lipase I-OSE_Labeled_AE
as O
an O
adverse O
reaction O
were O
reported O
for O
4 O
% O
( O
10/225 O
) O
of O
patients O
and O
were O
Grade O
3 O
for O
6 O
patients O
and O
Grade O
4 O
for O
1 O
patient O
. O

In O
the O
RCC B-Not_AE_Candidate
trials O
of O
VOTRIENT O
, O
clinical O
pancreatitis B-OSE_Labeled_AE
was O
observed O
in O
< O
1 O
% O
( O
4/586 O
) O
of O
patients O
. O

Pneumothorax B-NonOSE_AE
: O
Two O
of O
290 O
patients O
treated O
with O
VOTRIENT O
and O
no O
patient O
on O
the O
placebo O
arm O
in O
the O
randomized O
RCC B-Not_AE_Candidate
trial O
developed O
a O
pneumothorax B-OSE_Labeled_AE
. O

In O
the O
randomized O
trial O
of O
VOTRIENT O
for O
the O
treatment O
of O
STS B-Not_AE_Candidate
, O
pneumothorax B-OSE_Labeled_AE
occurred O
in O
3 O
% O
( O
8/240 O
) O
of O
patients O
treated O
with O
VOTRIENT O
and O
in O
no O
patients O
on O
the O
placebo O
arm O
. O

Bradycardia B-NonOSE_AE
: O
In O
the O
randomized O
trial O
of O
VOTRIENT O
for O
the O
treatment O
of O
RCC B-Not_AE_Candidate
, O
bradycardia B-OSE_Labeled_AE
based O
on O
vital O
signs O
( O
< O
60 O
beats O
per O
minute O
) O
was O
observed O
in O
19 O
% O
( O
52/280 O
) O
of O
patients O
treated O
with O
VOTRIENT O
and O
in O
11 O
% O
( O
16/144 O
) O
of O
patients O
on O
the O
placebo O
arm O
. O

Bradycardia B-OSE_Labeled_AE
was O
reported O
as O
an O
adverse O
reaction O
in O
2 O
% O
( O
7/290 O
) O
of O
patients O
treated O
with O
VOTRIENT O
compared O
with O
< O
1 O
% O
( O
1/145 O
) O
of O
patients O
treated O
with O
placebo O
. O

In O
the O
randomized O
trial O
of O
VOTRIENT O
for O
the O
treatment O
of O
STS B-Not_AE_Candidate
, O
bradycardia B-OSE_Labeled_AE
based O
on O
vital O
signs O
( O
< O
60 O
beats O
per O
minute O
) O
was O
observed O
in O
19 O
% O
( O
45/238 O
) O
of O
patients O
treated O
with O
VOTRIENT O
and O
in O
4 O
% O
( O
5/121 O
) O
of O
patients O
on O
the O
placebo O
arm O
. O

Bradycardia B-OSE_Labeled_AE
was O
reported O
as O
an O
adverse O
reaction O
in O
2 O
% O
( O
4/240 O
) O
of O
patients O
treated O
with O
VOTRIENT O
compared O
with O
< O
1 O
% O
( O
1/123 O
) O
of O
patients O
treated O
with O
placebo O
. O

6.2 O
Postmarketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
post-approval O
use O
of O
VOTRIENT O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
the O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Eye B-NonOSE_AE
Disorders I-NonOSE_AE
: O
Retinal B-OSE_Labeled_AE
detachment/ O
tear I-OSE_Labeled_AE
. O

Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
: O
Pancreatitis B-OSE_Labeled_AE
. O

